SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : TGEN - Targeted Genetics Corporation
TGEN 8.230+0.9%Nov 7 9:30 AM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Mike McFarland who wrote (426)1/13/2005 2:35:34 AM
From: 9wald9 of 557
 
I suspect that the street was put off bt the almost 5%
dilution of TGEN stock at a price of $1.52 a share in the
directed public offering to investors in Celladon Corporation.
I found it bullish that TGEN obtained the $6,000,000
cash and had committed to spend only $2,000,000 of it in the
collaboration with Celladon Corporation.
In regard to the second collaboration reported this month,
I am impressed with what Howard Robin, CEO at Sirna
said: "Through the collaboration announced today we are gaining access to Targeted Genetics’extensive capabilities in the development, clinical testing AND MANUFACTURE
of AAV-based products. We are excited to
explore the potential of AAV-RNAi therapies for Huntington’s Disease, and are very pleased to be working with the leading AAV-based product development company.”
Targeted Genetics CEO has in the past stressed the value
of the firm's ability in manufacturing.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News